OncoMatch/Clinical Trials/NCT04158635
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Is NCT04158635 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Bosentan and Gemcitabine for stage iii pancreatic cancer ajcc v8.
Treatment: Bosentan · Gemcitabine · Nab-paclitaxel — This phase I trial studies the side effects and best dose of bosentan and how well it works when given together with gemcitabine and nab-paclitaxel for the treatment of pancreatic cancer that cannot be removed by surgery (unresectable). Bosentan may block the hormone endothelin and prevent the growth and spread of pancreatic cancer. Drugs used in chemotherapy, such as gemcitabine and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bosentan with chemotherapy (gemcitabine and nab-paclitaxel) may work better in treating patients with pancreatic cancer compared to chemotherapy alone.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage III, IV
Lab requirements
Blood counts
anc ≥ 1500/mm3; platelets ≥ 100,000/mm3
Kidney function
creatinine clearance ≥ 60 ml/min
Liver function
ast, alt ≤ 1.5 x uln. patients with liver metastases ≤ 3 x uln. total serum bilirubin ≤ 1.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify